Chief Technology Officer
CurrentLaunched the commercialization of long, complex oligos through our Fully Enzymatic Synthesis (FES) technology and established technology roadmaps to continue the advancement of synthesis performance and capacity growth, overseeing R&D efforts and manufacturing transfer. Our offerings fills the frustrating gap of getting DNA at the sequence complexity, length and purity for cutting edge applications in CRISPR gene editing and protein engineering.Successfully completed key milestone and awarded an addition $4M for a DARPA-funded collaboration with GE Healthcare. The DARPA NOW program aims to develop a rapidly scalable and deployable mobile vaccine production platform used for pandemic-response countermeasures.